(Reuters) - Indivior Plc (L:INDV) on Monday said a U.S. Court granted-in-part a motion to expedite a rival's appeal of a preliminary injunction that blocked the sale of copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.
Earlier this month, a court had granted a preliminary injunction, preventing generic rival Dr. Reddy's Laboratories (NS:REDY) from re-launching its copycat version until the patent litigation is concluded or until the company prevails on an appeal of the injunction.
The U.S. court has not yet ruled on Dr. Reddy's motion to stay the preliminary injunction, Indivior said, adding that under the expedited schedule, oral arguments will be held during the first week of October.